Merck & Co. Inc. (MRK) on Tuesday announced it is discontinuing the clinical development program for nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. The drug was being studied in patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and other hematologic malignancies under the BELLWAVE umbrella.
Merck Scraps $6.7B Bet: Nemtabrutinib Program Halted After Safety Review
Get Merck & Co Alerts
Weekly insights + SMS alerts
Why Merck Hit the Brakes
The decision to stop the Phase 3 BELLWAVE-011 trial came after an external Data Monitoring Committee (eDMC) reviewed the results and suggested the benefits may not outweigh the risks in that study. Merck subsequently confirmed the move after reviewing the data in its totality.
But the company didn't stop there. It also decided to discontinue the broader BELLWAVE clinical development program, including the other Phase 3 studies: BELLWAVE-008 and BELLWAVE-010.
The Terns Pharmaceuticals Deal and Earlier Promising Data
Merck added the drug through a deal with Terns Pharmaceuticals Inc. for $53.00 per share in cash, an approximate equity value of $6.7 billion.
At EHA 2023, Merck presented updated Phase 1/2 results from the BELLWAVE-001 trial, evaluating nemtabrutinib (MK-1026) in B-cell malignancies. Nemtabrutinib 65 mg once daily (QD) generated a 32% ORR, a 24.4-month mDOR, and a 26.3-month mPFS in CLL/SLL patients.
MRK Price Action: Merck & Co shares were down 2.26% at $140.13 at the time of publication on Wednesday, according to market data.
More News

Dow Drops as Nvidia Slips After Earnings, Dollar Hits 19-Month High: Stock Market Today

Fed Minutes: 'Almost All' Officials See More Hikes, and AI Debt Is Now on the Radar

Nvidia's $105 Billion OpenAI Bet Comes With a 20-Year Catch

Waller Warns of a December Rate Shock. Here's How TIPS ETFs Handle That Kind of Heat.

Wall Street Says the AI Trade Is Dead. ETF Investors Are Quietly Buying the Dip

Bitcoin's Next Stop: $54,000, $38,000, Or A Surprise Rebound?

Lowe's Q3 Beat Came With a Tariff Refund Twist, and JPMorgan Says 2026 Is the Clean Slate for 2027

Newmont Stock Sinks 6% as Gold Loses Its Shine Below $3,800
Get Merck & Co Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all news
Dow Drops as Nvidia Slips After Earnings, Dollar Hits 19-Month High: Stock Market Today

Fed Minutes: 'Almost All' Officials See More Hikes, and AI Debt Is Now on the Radar

Nvidia's $105 Billion OpenAI Bet Comes With a 20-Year Catch

Waller Warns of a December Rate Shock. Here's How TIPS ETFs Handle That Kind of Heat.

Wall Street Says the AI Trade Is Dead. ETF Investors Are Quietly Buying the Dip

Bitcoin's Next Stop: $54,000, $38,000, Or A Surprise Rebound?

Lowe's Q3 Beat Came With a Tariff Refund Twist, and JPMorgan Says 2026 Is the Clean Slate for 2027






